Category: Guest content

Tracking 20 Years of Compound-to-Target Output from Literature and Patents

This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…


Celgene vs. Dr. Reddy’s Revlimid patent infringement case depends on polymorph stability; lack thereof may favor Celgene position – experts

This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…
The post C…


Making Medicines Affordable: A National Imperative

Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this need is not being served adequately by the biopharmaceutical sector,…
The post Making Medicines Affordable…


Patent Protection Strategies

This article was originally published by Himanshu Gupta, Suresh Kumar, Saroj Kumar Roy, and R. S. Gaud at J Pharm Bioallied Sci. 2010 Jan-Mar; 2(1): 2–7. Abstract It is widely recognized…
The post Patent Protection Strategies appeared first on Dr…


Leveraging affordable innovation to tackle India’s healthcare challenge

This article was originally published by Kiran Mazumdar Shaw in IIMB Management Review under a Creative Commons license. Abstract Affordable innovation, which presents ways to innovate, be flexible, and do more with…
The post Leveraging affordabl…


A Comparison of Generic Drug Prices in Seven European Countries: A Methodological Analysis

This paper was originally published by Olivier J. Wouters and Panos G. Kanavos in BMC Health Services Research  2017 17:242 https://doi.org/10.1186/s12913-017-2184-5 ©  The Author(s). 2017 Abstract Background Policymakers and researchers frequently com…


Calculating the Regulatory Review Period for Patent Term Extension

Identifying the testing phase can be tricky This is a guest post from Nicole Stakleff and Kyle Dolinsky in Pepper Hamilton’s Health Sciences Department. Nicole can be contacted at [email protected] Calculating…
The post Calculating the Regulator…


Patent Term Extension for Drugs not Limited to new Chemical Entities

Companies developing a new drug product, even if it is not an NCE, should explore ways to increase the likelihood of obtaining and maximizing PTE This is a guest post…
The post Patent Term Extension for Drugs not Limited to new Chemical Entities appear…


How to Obtain Multiple Patent Term Extensions for a Single Product

The value of obtaining multiple PTEs on different patents could incentivize innovators to revise their clinical development programs This is a guest post from Nicole Stakleff and Kyle Dolinsky in…
The post How to Obtain Multiple Patent Term Extensions …


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: